Dermata Therapeutics, INC

Dermata Therapeutics shareholders approved key proposals including an equity plan expansion and warrant repricing.

Dermata Therapeutics announced its strategic shift to direct-to-consumer skincare with the launch of its 'Tome' brand and reported Q1 2026 financial results, including $2.0 million in net proceeds from ATM financing.

Dermata Therapeutics announced a strategic pivot to direct-to-consumer skincare products under the new brand Tome, alongside reporting its financial results for the year ended December 31, 2025, and securing $15.4 million in financing.

Mary Fisher has resigned from Dermata Therapeutics' Board of Directors, effective March 31, 2026, due to a new employer policy.

Dermata Therapeutics, Inc. announced a change in its independent registered public accounting firm, dismissing Baker Tilly US, LLP and appointing CBIZ CPAs P.C., following audit reports that included a 'going concern' explanatory paragraph.

Dermata Therapeutics, Inc. has increased the maximum aggregate offering amount of its common stock under its At The Market offering agreement by an additional $705,000.

Dermata Therapeutics reports Q1 2026 results, detailing a strategic pivot to direct-to-consumer skincare and ongoing legal challenges.

Dermata Therapeutics, Inc. announced a strategic shift to over-the-counter dermatology products following positive Phase 3 trial results for XYNGARI, while reporting continued net losses and a going concern warning.

Dermata Therapeutics, a clinical-stage dermatology company, reported a reduced net loss in Q2 2025 and positive Phase 3 trial results for its lead acne candidate XYNGARI, but faces significant going concern doubts and Nasdaq delisting risk.

Dermata Therapeutics reports positive topline results from its Phase 3 STAR-1 clinical trial for XYNGARI and provides a financial update for the quarter ended March 31, 2025.

Dermata Therapeutics reports a net loss of $3.2 million for the third quarter of 2024, with increased research and development expenses due to ongoing Phase 3 clinical trials.

Dermata Therapeutics reports a net loss of $2.8 million for the second quarter of 2024, with ongoing clinical trial expenses impacting financials.

Dermata Therapeutics shifts focus from prescription drugs to direct-to-consumer and B2B skincare products, reporting continued losses and a going concern warning.

Dermata Therapeutics reports its 2024 financial results and provides an update on the clinical development of its lead product candidates, XYNGARI and DMT410, including the ongoing Phase 3 trial for acne and a collaboration with Revance for hyperhidrosis.

Dermata Therapeutics' 10-K filing details its capital structure, including common and preferred stock, warrants, and anti-takeover provisions, alongside its financial performance and clinical development pipeline.

Dermata Therapeutics Director Kathleen D. Scott acquired 11 shares of common stock for $1.19 per share.

Dermata Therapeutics' SVP of Regulatory Affairs, Maria E. Bedoya-Toro Munera, plans to acquire 1,000 shares of common stock at $1.27 per share on February 17, 2026.

Dermata Therapeutics' SVP of Regulatory Affairs, Maria E Bedoya-Toro Munera, was granted 9,000 stock options with an exercise price of $2.18.

Dermata Therapeutics Director Kathleen D. Scott acquired 2,500 stock options with an exercise price of $2.18, vesting monthly over one year.

Dermata Therapeutics Director Andrew Seth Sandler was granted 2,500 stock options with an exercise price of $2.18, vesting monthly over one year.

Dermata Therapeutics, Inc. granted 18,000 stock options to Senior VP and CDO Christopher J. Nardo with an exercise price of $2.18.

Dermata Therapeutics has issued its 2026 proxy statement seeking stockholder approval for director elections, auditor ratification, warrant issuances, and an equity plan amendment.

Dermata Therapeutics, Inc. has officially filed a Definitive Additional Materials proxy statement (DEFA14A) with the U.S. Securities and Exchange Commission.

Dermata Therapeutics, Inc. is calling an Annual Meeting of Stockholders to address critical Nasdaq listing compliance issues, including a proposed reverse stock split and the ratification of recent dilutive warrant issuances that raised over $8 million.

Dermata Therapeutics is holding its annual meeting of stockholders on May 7, 2024, to vote on key proposals including a reverse stock split, an amendment to the equity incentive plan, and the ratification of its independent auditor.

Dermata Therapeutics is asking stockholders to approve an amendment to its equity incentive plan and a reverse stock split at its upcoming annual meeting on May 7, 2024.

Dermata Therapeutics CFO Kyri K. Van Hoose reports beneficial ownership of 9.0% of the company's common stock following a private placement and warrant amendments.

Gerald T. Proehl, President and CEO of Dermata Therapeutics, Inc., updated his beneficial ownership to 17.3% of the company's common stock.

Dermata Therapeutics CEO Gerald T. Proehl filed an amendment to his Schedule 13D, confirming beneficial ownership of 19.6% of the company's common stock.

Dermata Therapeutics' CEO Gerald T. Proehl increased his beneficial ownership to 24.7% following participation in a private placement, while Proehl Investment Ventures LLC's stake fell below 5%.

Gerald T. Proehl and Proehl Investment Ventures LLC filed an amended Schedule 13D to correct their reported beneficial ownership percentage in Dermata Therapeutics, Inc. to 13.3% based on an updated outstanding share count.

Gerald T. Proehl and Proehl Investment Ventures LLC have filed Amendment No. 6 to their Schedule 13D, reaffirming their beneficial ownership of 7.8% of Dermata Therapeutics, Inc.'s common stock as of March 27, 2025.

Dermata Therapeutics, Inc. has filed a Schedule 13G detailing beneficial ownership of common stock by Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC.

Bigger Capital Fund LP and associated entities have filed an amendment to their Schedule 13G, reporting a reduction in their beneficial ownership of Dermata Therapeutics, Inc. to below 5%.

Michael Bigger and affiliated entities, Bigger Capital and District 2 Capital, have disclosed a combined beneficial ownership of 9.89% in Dermata Therapeutics, Inc.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 5.5% beneficial ownership stake in Dermata Therapeutics, Inc.

A group of investment entities and an individual, led by Michael Bigger, have disclosed beneficial ownership of 7.43% of Dermata Therapeutics, Inc.'s common stock.

Armistice Capital, LLC and Steven Boyd have disclosed a 9.99% beneficial ownership stake in Dermata Therapeutics, Inc. common stock as of June 30, 2025.